Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab

被引：0
|
作者：
Pinheiro, Elaine M.
Hinton, Marlene
Mangadu, Ruban
Cai, Mingmei
Phan, Uyen
Nebozhyn, Michael
Hirsch, Heather
Loboda, Andrey
Javaid, Sarah
Wang, Yaolin
Sriram, Venkataraman
Phillips, Joseph H.
McClanahan, Tern
Long, Brian
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
543
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
    Ott, P. A.
    Piha-Paul, S. A.
    Munster, P.
    Pishvaian, M. J.
    Van Brummelen, E. M. J.
    Cohen, R. B.
    Gomez-Roca, C.
    Ejadi, S.
    Stein, M.
    Chan, E.
    Simonelli, M.
    Morosky, A.
    Saraf, S.
    Emancipator, K.
    Koshiji, M.
    Bennouna, J.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1036 - 1041
  • [32] Myeloid Maturity: ATRA to Enhance Anti-PD-1?
    Olson, Daniel J.
    Luke, Jason J.
    CLINICAL CANCER RESEARCH, 2023, 29 (07) : 1167 - 1169
  • [33] Evaluating anti-tumor activity of the human anti-PD-1 antibody pembrolizumab using humanized mouse models
    Linn, Douglas E.
    Cristescu, Razvan
    Ray, Kallol
    Zhang, Shuli
    Dhandapani, Sripriya
    Kaliyaperumal, Sarav
    Yearley, Jennifer H.
    Long, Brian J.
    CANCER RESEARCH, 2017, 77
  • [34] Preclinical characterization of SAR445877, an anti-PD-1 antibody-IL-15 mutein fusion protein with robust antitumor efficacy as monotherapy and in combination with PD-L1 blockade
    Bernardo, Marie
    Zhang, Yu-An
    Lu, Dan
    Martomo, Stella
    Menas, Fatima
    Zhu, Chen
    Perez, Raymond
    Patel, Jeegar
    Shaffer, Donald
    Li, Xiangming
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Rationale of Using the Combination of Anti-PD-1 Antibody and Anti-IL-8 Antibody for the Pancreatic Cancer Treatment
    Li, P.
    Rozich, N.
    Wang, J.
    Gai, J.
    Wang, J.
    Xu, Y.
    Herbst, B.
    Yu, R.
    Muth, S.
    Niu, N.
    Li, K.
    Fune, V.
    Osipov, A.
    Wolfgang, C. L.
    Lei, M.
    Liang, T.
    Zheng, L.
    PANCREAS, 2021, 50 (07) : 1074 - 1074
  • [36] RATIONALE OF USING THE COMBINATION OF ANTI-PD-1 ANTIBODY AND ANTI-IL-8 ANTIBODY FOR THE PANCREATIC CANCER TREATMENT
    Li, P.
    Rozich, N.
    Wang, J.
    Gai, J.
    Wang, J.
    Xu, Y.
    Herbst, B.
    Yu, R.
    Muth, S.
    Niu, N.
    Li, K.
    Fune, V.
    Osipov, A.
    Wolfgang, C.
    Lei, M.
    Liang, T.
    Zheng, L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A24 - A25
  • [37] Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice
    Burova, Elena
    Hermann, Aynur
    Dai, Jie
    Ullman, Erica
    Halasz, Gabor
    Potocky, Terra
    Hong, Seongwon
    Liu, Matt
    Allbritton, Omaira
    Woodruff, Amy
    Pei, Jerry
    Rafique, Ashique
    Poueymirou, William
    Martin, Joel
    MacDonald, Douglas
    Olson, William C.
    Murphy, Andrew
    Ioffe, Ella
    Thurston, Gavin
    Mohrs, Markus
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (11) : 2051 - 2062
  • [38] Enhancement of anti-PD-1 antitumor efficacy in syngeneic preclinical models by the angiogenesis inhibitor lucitanib
    Dusek, Rachel L.
    Robillard, Liliane
    Harding, Thomas C.
    Simmons, Andrew D.
    Minh Nguyen
    CANCER RESEARCH, 2019, 79 (13)
  • [39] The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer
    Orlandella, Rachael M.
    Turbitt, William J.
    Gibson, Justin T.
    Boi, Shannon K.
    Li, Peng
    Smith, Daniel L., Jr.
    Norian, Lyse A.
    CANCERS, 2020, 12 (10) : 1 - 19
  • [40] The efficacy of anti-PD-1 antibody for IVLBCL in humanized immune system mouse model
    Takai, Mika
    Shimada, Kazuyuki
    Kiyoi, Hitoshi
    CANCER SCIENCE, 2024, 115 : 1018 - 1018
12345